News stories about Adamas Pharmaceuticals (NASDAQ:ADMS) have trended somewhat positive on Friday, according to Accern. The research group identifies negative and positive news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Adamas Pharmaceuticals earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned news articles about the specialty pharmaceutical company an impact score of 46.2118983552535 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the news articles that may have effected Accern Sentiment Analysis’s scoring:
- Adamas Pharmaceuticals: Continued Upside In 2018 And Beyond – Seeking Alpha (seekingalpha.com)
- Adamas Pharmaceuticals, Inc. (ADMS) : Investors need to focus on Analysts Rating – Wall Street Morning (wallstreetmorning.com)
- Adamas (ADMS) Launches Dyskinesia Drug in the US, Stock Up – Nasdaq (nasdaq.com)
- Facts About In Play Stocks – Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) – Alpha Beta Stock (alphabetastock.com)
- Keen Investors Taking a Closer Look at Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) – Newburgh Gazette (newburghgazette.com)
Shares of Adamas Pharmaceuticals (NASDAQ ADMS) opened at $37.39 on Friday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 8.32 and a current ratio of 8.35. Adamas Pharmaceuticals has a 52 week low of $13.50 and a 52 week high of $38.75. The stock has a market cap of $851.70, a P/E ratio of -11.13 and a beta of 1.13.
Several equities analysts recently commented on ADMS shares. Evercore ISI started coverage on shares of Adamas Pharmaceuticals in a research report on Monday, October 30th. They set an “outperform” rating for the company. Cowen set a $55.00 price target on shares of Adamas Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, December 13th. Zacks Investment Research raised shares of Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 10th. Northland Securities started coverage on shares of Adamas Pharmaceuticals in a research report on Wednesday, November 29th. They set an “outperform” rating for the company. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating and set a $30.00 price target on shares of Adamas Pharmaceuticals in a research report on Wednesday, October 4th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the stock. Adamas Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $44.86.
COPYRIGHT VIOLATION NOTICE: “Adamas Pharmaceuticals (ADMS) Getting Somewhat Favorable News Coverage, Study Finds” was first published by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this story on another site, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this story can be read at https://stocknewstimes.com/2018/01/19/adamas-pharmaceuticals-adms-given-news-impact-score-of-0-10.html.
Adamas Pharmaceuticals Company Profile
Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.